Real-world Efficacy and Safety of Stapokibart in Children and Adolescents with Moderate-to-severe Atopic Dermatitis: A Retrospective Study

Paediatric real-world evidence for stapokibart in moderate-to-severe atopic dermatitis (AD) is scarce. We retrospectively analysed 55 patients aged 6–17 years treated at a single centre for 16 weeks using weight-tiered dosing (<30 kg: 600 mg loading, then 300 mg every 4 weeks; ≥30 kg: 600 mg loadin...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Lubing Li, Yuqi Chen, Minmin Lin, Liyue Hou, Yijia Shao, Yihui Li, Junyi Shao, Xinhao Yu, Tongyao Chen, Zhiming Li
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Medical Journals Sweden 2026-05-01
Edice:	Acta Dermato-Venereologica
Témata:	atopic dermatitis children adolescent treatment outcome safety stapokibart
On-line přístup:	https://medicaljournalssweden.se/actadv/article/view/46103
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!